Print this page
Sarcoma
-
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
Protocol: 102302Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-Sensitive Recurrent Ovarian Cancer (TroFuse-022/GOG-3103/ENGOT-ov84).
Protocol: 102501Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR alpha-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Protocol: 102502Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6.
Protocol: 102503Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
Novel Immune Checkpoint Expression on Circulating Tumor Cells of Sarcomas.
Protocol: 112103Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints
Lung -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified -
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma.
Protocol: 112205Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma.
Protocol: 112303Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints -
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors.
Protocol: 112401-01APrincipal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site
- 1
- 2